EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Determining cost-saving risk thresholds for statin use

Afschin Gandjour iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0318454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Afschin Gandjour. Beteiligte Einrichtung: Frankfurt School of Finance & Management, Frankfurt, Germany. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Cost Savings. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The German government has recently drafted a bill proposing a reduction in the prescription threshold for statin use. This study aims to determine the cost-saving risk threshold for statin use in Germany to inform this proposed change.

Methods

An economic evaluation utilizing a decision-analytic model was performed, using secondary data to compare statin use versus no statin use from the perspective of German sickness fund insurees. The analysis focused on cost savings from avoided cardiovascular (CV) events, translating these avoided events into net savings after accounting for treatment costs and potential side effects. The study considered the German adult population insured by sickness funds and used a lifetime horizon for the analysis.

Results

The maximum number needed to treat (NNT) to achieve cost savings over 10 years was found to be 39, leading to a minimum CV risk threshold for savings of 10.2%. It was estimated that approximately 19% of the adult population in Germany has a 10-year CV risk of ≥ 10.2%, potentially avoiding between 271,739 and 581,363 CV events over 10 years, with net population savings of approximately €15 billion.

Conclusions

A threshold for statin prescription in Germany set at a 10.2% 10-year CV risk could significantly increase the number of patients benefiting from statin therapy, reducing CV events and generating substantial cost savings. These findings suggest that adjustments to prescription guidelines could improve cardiovascular outcomes and economic efficiency within the German healthcare system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesCost SavingsHumansGermanyCost-Benefit AnalysisAdultMiddle AgedMaleFemale

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Frankfurt School of Finance & Management, Frankfurt, Germany.

ORCID-Profile: Afschin Gandjour

Zitieren

APA

Gandjour, A. (2025). Determining cost-saving risk thresholds for statin use. PLOS ONE. https://doi.org/10.1371/journal.pone.0318454

Vancouver

Gandjour A. Determining cost-saving risk thresholds for statin use. PLOS ONE. 2025. doi:10.1371/journal.pone.0318454

BibTeX
@article{Gandjour2025,
  author = {Gandjour, Afschin},
  title = {Determining cost-saving risk thresholds for statin use},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0318454}
}
Kostenlos starten →